Anshabo et al.

CDK9 in Cancer

173. Abdullah C, Wang X, Becker D. Expression Analysis and Molecular Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChe
Targeting of Cyclin-Dependent Kinases in Advanced Melanoma. Cell (2017) 12(21):1776–93. doi: 10.1002/cmdc.201700447
Cycle (2011) 10(6):977–88. doi: 10.4161/cc.10.6.15079 193. Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, et al. Cdki-73: An
174. Bragelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Bohm Orally Bioavailable and Highly Efficacious CDK9 Inhibitor Against Acute
S, et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Myeloid Leukemia. Invest New Drugs (2019) 37(4):625–35. doi: 10.1007/
Lethal Target in NUT Midline Carcinoma. Cell Rep (2017) 20(12):2833–45. s10637-018-0661-2
doi: 10.1016/j.celrep.2017.08.082 194. O’Reilly A, Murphy J, Rawe S, Garvey M. Chronic Lymphocytic Leukemia: A
175. Storch K, Cordes N. The Impact of CDK9 on Radiosensitivity, DNA Damage Review of Front-line Treatment Options, With a Focus on Elderly Cll
Repair and Cell Cycling of HNSCC Cancer Cells. Int J Oncol (2016) 48 Patients. Clin Lymphoma Myeloma Leuk (2018) 18(4):249–56.
(1):191–8. doi: 10.3892/ijo.2015.3246 doi: 10.1016/j.clml.2018.02.003
176. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. 195. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1
AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Expression has In Vitro and In Vivo Significance in Chronic Lymphocytic
Subunit of MLL Chimeras, can Link Transcription Elongation to Leukemia. Leukemia and is Associated With Other Poor Prognostic Markers. Blood
Mol Cell (2010) 37(3):429–37. doi: 10.1016/j.molcel.2010.01.026 (2008) 112(9):3807–17. doi: 10.1182/blood-2008-05-157131
177. Muntean AG, Hess JL. The Pathogenesis of Mixed-Lineage Leukemia. Annu 196. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-Cell Receptor
Rev Pathol (2012) 7:283–301. doi: 10.1146/annurev-pathol-011811-132434 Signaling in Chronic Lymphocytic Leukemia. Blood (2011) 118(16):4313–20.
178. Argiropoulos B, Humphries RK. Hox Genes in Hematopoiesis and doi: 10.1182/blood-2011-06-338855
Leukemogenesis. Oncogene (2007) 26(47):6766–76. doi: 10.1038/ 197. Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, et al. The
sj.onc.1210760 Novel Cyclin-Dependent Kinase Inhibitor Dinaciclib (SCH727965)
179. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New Promotes Apoptosis and Abrogates Microenvironmental Cytokine
Insights to the MLL Recombinome of Acute Leukemias. Leukemia (2009) 23 Protection in Chronic Lymphocytic Leukemia Cells. Leukemia (2012) 26
(8):1490–9. doi: 10.1038/leu.2009.33 (12):2554–7. doi: 10.1038/leu.2012.144
180. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 198. Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, et al. A
Inhibition Selectively Kills Childhood Acute Lymphoblastic Leukemia Cells Novel Cdk9 Inhibitor Preferentially Targets Tumor Cells and Synergizes
With High Levels of FLT3 Expression. Blood (2005) 105(2):812–20. With Fludarabine. Oncotarget (2014) 5(2):375–85. doi: 10.18632/
doi: 10.1182/blood-2004-06-2498 oncotarget.1568
181. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, 199. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol
et al. A Role for the MLL Fusion Partner ENL in Transcriptional Elongation Administered Using a Pharmacologically Derived Schedule is Associated
and Chromatin Modification. Blood (2007) 110(13):4445–54. doi: 10.1182/ With Marked Clinical Efficacy in Refractory, Genetically High-Risk Chronic
blood-2007-05-090514 Lymphocytic Leukemia. Blood (2007) 109(2):399–404. doi: 10.1182/blood-
182. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, et al. Linking 2006-05-020735
H3K79 Trimethylation to Wnt Signaling Through a Novel Dot1-containing 200. Ghia P, Scarfo L, Perez S, Pathiraja K, Derosier M, Small K, et al. Efficacy and
Complex (Dotcom). Genes Dev (2010) 24(6):574–89. doi: 10.1101/ Safety of Dinaciclib vs Ofatumumab in Patients With Relapsed/Refractory
gad.1898410 Chronic Lymphocytic Leukemia. Blood (2017) 129(13):1876–8. doi: 10.1182/
183. Maethner E, Garcia-Cuellar MP, Breitinger C, Takacova S, Divoky V, Hess blood-2016-10-748210
JL, et al. Mll-ENL Inhibits Polycomb Repressive Complex 1 to Achieve 201. Wang S, Fischer PM. Cyclin-Dependent Kinase 9: A Key Transcriptional
Efficient Transformation of Hematopoietic Cells. Cell Rep (2013) 3(5):1553– Regulator and Potential Drug Target in Oncology, Virology and Cardiology.
66. doi: 10.1016/j.celrep.2013.03.038 Trends Pharmacol Sci (2008) 29(6):302–13. doi: 10.1016/j.tips.2008.03.003
184. McCalmont H, Li KL, Jones L, Toubia J, Bray SC, Casolari DA, et al. Efficacy 202. Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell
of Combined CDK9/BET Inhibition in Preclinical Models of MLL- Lymphomas: Diagnostic and Molecular Aspects. Genes (Basel) (2017) 8
rearranged Acute Leukemia. Blood Adv (2020) 4(2):296–300. doi: 10.1182/ (4):1–23. doi: 10.3390/genes8040116
bloodadvances.2019000586 203. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA (2019) 321
185. Libura M, Asnafi V, Tu A, Delabesse E, Tigaud I, Cymbalista F, et al. FLT3 and (3):288–300. doi: 10.1001/jama.2018.19323
MLL Intragenic Abnormalities in AML Reflect a Common Category of Genotoxic 204. Baird RD, Caldas C. Genetic Heterogeneity in Breast Cancer: The Road to
Stress. Blood (2003) 102(6):2198–204. doi: 10.1182/blood-2003-01-0162 Personalized Medicine? BMC Med (2013) 11:151. doi: 10.1186/1741-7015-11-151
186. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer 205. Mitra P, Pereira LA, Drabsch Y, Ramsay RG, Gonda TJ. Estrogen Receptor-
ML, et al. Inhibition of FLT3 in MLL. Validation of a Therapeutic Target Alpha Recruits P-TEFb to Overcome Transcriptional Pausing in Intron 1 of
Identified by Gene Expression Based Classification. Cancer Cell (2003) 3 the MYB Gene. Nucleic Acids Res (2012) 40(13):5988–6000. doi: 10.1093/
(2):173–83. doi: 10.1016/s1535-6108(03)00003-5 nar/gks286
187. Grafone T, Palmisano M, Nicci C, Storti S. An Overview on the Role of 206. Sengupta S, Biarnes MC, Jordan VC. Cyclin Dependent Kinase-9 Mediated
FLT3-tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Transcriptional De-Regulation of cMYC as a Critical Determinant of
Treatment. Oncol Rev (2012) 6(1):e8. doi: 10.4081/oncol.2012.e8 Endocrine-Therapy Resistance in Breast Cancers. Breast Cancer Res Treat
188. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, et al. Mll- (2014) 143(1):113–24. doi: 10.1007/s10549-013-2789-2
AF9 and FLT3 Cooperation in Acute Myelogenous Leukemia: Development 207. Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast
of a Model for Rapid Therapeutic Assessment. Leukemia (2008) 22(1):66–77. Cancer. Curr Breast Cancer Rep (2014) 6(3):154–8. doi: 10.1007/s12609-014-0152-1
doi: 10.1038/sj.leu.2404951 208. Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX. Inhibition of Cyclin
189. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti- Dependent Kinase 9 by Dinaciclib Suppresses Cyclin B1 Expression and
Apoptotic Mcl-1 is Essential for the Development and Sustained Growth of Tumor Growth in Triple Negative Breast Cancer. Oncotarget (2016) 7
Acute Myeloid Leukemia. Genes Dev (2012) 26(2):120–5. doi: 10.1101/ (35):56864–75. doi: 10.18632/oncotarget.10870
gad.182980.111 209. Gelmann EP. Molecular Biology of the Androgen Receptor. J Clin Oncol
190. Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, et al. Mcl1 (2002) 20(13):3001–15. doi: 10.1200/JCO.2002.10.018
Haploinsufficiency Protects Mice From Myc-induced Acute Myeloid 210. Lee DK, Duan HO, Chang C. Androgen Receptor Interacts With the Positive
Leukemia. J Clin Invest (2010) 120(6):2109–18. doi: 10.1172/JCI39964 Elongation Factor P-TEFb and Enhances the Efficiency of Transcriptional
191. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, et al. Elongation. J Biol Chem (2001) 276(13):9978–84. doi: 10.1074/jbc.M002285200
Elevated Expression of the Apoptotic Regulator Mcl-1 At the Time of Leukemic 211. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, et al.
Relapse. Blood (1998) 91(3):991–1000. doi: 10.1182/blood.V91.3.991 CDK9 Regulates AR Promoter Selectivity and Cell Growth Through Serine
192. Lucking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, 81 Phosphorylation. Mol Endocrinol (2010) 24(12):2267–80. doi: 10.1210/
et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, me.2010-0238

Frontiers in Oncology | www.frontiersin.org 23 May 2021 | Volume 11 | Article 678559